| # | Title | Journal | Year | Citations |
|---|
| 1 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis | Lancet Oncology, The | 2016 | 719 |
| 2 | Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | Annals of Oncology | 2018 | 387 |
| 3 | Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial | Lancet Oncology, The | 2014 | 239 |
| 4 | Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort | British Journal of Cancer | 2015 | 151 |
| 5 | FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort | Annals of Surgical Oncology | 2015 | 145 |
| 6 | Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study | International Journal of Cancer | 2020 | 56 |
| 7 | Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives | Drugs | 2020 | 42 |
| 8 | Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study | British Journal of Cancer | 2018 | 37 |
| 9 | Checkpoint inhibitors and gastrointestinal immune-related adverse events | Current Opinion in Oncology | 2016 | 35 |
| 10 | Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer | International Journal of Cancer | 2020 | 26 |
| 11 | Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy | Clinical Cancer Research | 2018 | 23 |
| 12 | Management of gastric neuro-endocrine tumours in a large French national cohort (GTE) | Endocrine | 2017 | 16 |
| 13 | Resection of Late Pulmonary Metastases from Pancreatic Adenocarcinoma: Is Surgery an Option? | Cancer Investigation | 2015 | 14 |
| 14 | Role of circulating tumor DNA in the management of patients with colorectal cancer | Clinics and Research in Hepatology and Gastroenterology | 2018 | 14 |
| 15 | Impact of diabetes and metformin use on recurrence and outcome in stage II–III colon cancer patients—A pooled analysis of three adjuvant trials | European Journal of Cancer | 2022 | 13 |
| 16 | FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial | Annals of Oncology | 2015 | 12 |
| 17 | Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis | Investigational New Drugs | 2015 | 10 |
| 18 | Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial | PLoS ONE | 2015 | 7 |
| 19 | Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX). | Journal of Clinical Oncology | 2018 | 7 |
| 20 | Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’ | British Journal of Cancer | 2016 | 3 |
| 21 | High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer | Cellular Oncology (Dordrecht) | 2020 | 3 |
| 22 | Chemosensitivity in ovarian metastases from gastric cancer: A case series | Clinics and Research in Hepatology and Gastroenterology | 2013 | 1 |
| 23 | Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study | Annals of Oncology | 2018 | 1 |
| 24 | Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial) | Annals of Oncology | 2018 | 1 |
| 25 | Unresectable liver metastases in colorectal cancer: review of current strategies | Minerva Chirurgica | 2016 | 1 |
| 26 | Hereditary gastrointestinal cancers: why genetic counseling matters | Annals of Oncology | 2019 | 0 |
| 27 | Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies. | Journal of Clinical Oncology | 2018 | 0 |
| 28 | PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial). | Journal of Clinical Oncology | 2018 | 0 |
